These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 27839966)
1. Single nucleotide polymorphisms of the DGKB and VCAM1 genes are associated with granulocyte colony stimulating factor-mediated peripheral blood stem cell mobilization. Mishima S; Matsuda C; Ishihara T; Nagase M; Taketani T; Nagai A Transfus Apher Sci; 2017 Apr; 56(2):154-159. PubMed ID: 27839966 [TBL] [Abstract][Full Text] [Related]
2. Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies. Szmigielska-Kaplon A; Szemraj J; Hamara K; Robak M; Wolska A; Pluta A; Czemerska M; Krawczynska A; Jamroziak K; Szmigielska K; Robak T; Wierzbowska A Biol Blood Marrow Transplant; 2014 Jul; 20(7):986-91. PubMed ID: 24680978 [TBL] [Abstract][Full Text] [Related]
3. Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors. Martín-Antonio B; Carmona M; Falantes J; Gil E; Baez A; Suarez M; Marín P; Espigado I; Urbano-Ispizua A Haematologica; 2011 Jan; 96(1):102-9. PubMed ID: 20851866 [TBL] [Abstract][Full Text] [Related]
4. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622 [TBL] [Abstract][Full Text] [Related]
5. [The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization]. Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2966-70. PubMed ID: 17288807 [TBL] [Abstract][Full Text] [Related]
6. Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF. Garciaz S; Sfumato P; Granata A; Imbert AM; Fournel C; Calmels B; Lemarie C; Chiaroni J; Blaise D; Boher JM; Picard C; Chabannon C; di Cristofaro J PLoS One; 2020; 15(3):e0228878. PubMed ID: 32134938 [TBL] [Abstract][Full Text] [Related]
9. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358 [TBL] [Abstract][Full Text] [Related]
10. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
12. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor. Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594 [TBL] [Abstract][Full Text] [Related]
13. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related]
14. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Pelus LM; Bian H; Fukuda S; Wong D; Merzouk A; Salari H Exp Hematol; 2005 Mar; 33(3):295-307. PubMed ID: 15730853 [TBL] [Abstract][Full Text] [Related]
15. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278 [TBL] [Abstract][Full Text] [Related]
16. The effect of cholesterol levels on hematopoietic stem cell mobilization. Donmez A; Kabaroglu C; Arik B; Tombuloglu M Transfus Apher Sci; 2012 Aug; 47(1):9-12. PubMed ID: 22465757 [TBL] [Abstract][Full Text] [Related]
17. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. Sosman JA; Stiff P; Moss SM; Sorokin P; Martone B; Bayer R; van Besien K; Devine S; Stock W; Peace D; Chen Y; Long C; Gustin D; Viana M; Hoffman R J Clin Oncol; 2001 Feb; 19(3):634-44. PubMed ID: 11157013 [TBL] [Abstract][Full Text] [Related]
18. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF]. Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058 [TBL] [Abstract][Full Text] [Related]
19. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients. Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657 [TBL] [Abstract][Full Text] [Related]
20. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]